NEXMI_HUMAN
ID NEXMI_HUMAN Reviewed; 1516 AA.
AC Q5QGS0; A7YY87; Q5JUX9; Q8IVE9;
DT 31-OCT-2006, integrated into UniProtKB/Swiss-Prot.
DT 04-JAN-2005, sequence version 1.
DT 03-AUG-2022, entry version 136.
DE RecName: Full=Neurite extension and migration factor {ECO:0000305};
DE AltName: Full=XLMR protein related to neurite extension {ECO:0000303|PubMed:24071057};
DE Short=XPN {ECO:0000303|PubMed:24071057};
GN Name=NEXMIF {ECO:0000312|HGNC:HGNC:29433};
GN Synonyms=KIAA2022 {ECO:0000312|HGNC:HGNC:29433};
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE [MRNA], INVOLVEMENT IN XLID98, TISSUE SPECIFICITY, AND
RP CHROMOSOMAL REARRANGEMENT.
RX PubMed=15466006; DOI=10.1136/jmg.2004.021626;
RA Cantagrel V., Lossi A.-M., Boulanger S., Depetris D., Mattei M.-G.,
RA Gecz J., Schwartz C.E., Van Maldergem L., Villard L.;
RT "Disruption of a new X linked gene highly expressed in brain in a family
RT with two mentally retarded males.";
RL J. Med. Genet. 41:736-742(2004).
RN [2]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC TISSUE=Brain;
RA Nagase T., Kikuno R., Ohara O.;
RT "The nucleotide sequence of a long cDNA clone isolated from human.";
RL Submitted (NOV-2002) to the EMBL/GenBank/DDBJ databases.
RN [3]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX PubMed=15772651; DOI=10.1038/nature03440;
RA Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A., Lovell F.L.,
RA Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G., Jones M.C.,
RA Hurles M.E., Andrews T.D., Scott C.E., Searle S., Ramser J., Whittaker A.,
RA Deadman R., Carter N.P., Hunt S.E., Chen R., Cree A., Gunaratne P.,
RA Havlak P., Hodgson A., Metzker M.L., Richards S., Scott G., Steffen D.,
RA Sodergren E., Wheeler D.A., Worley K.C., Ainscough R., Ambrose K.D.,
RA Ansari-Lari M.A., Aradhya S., Ashwell R.I., Babbage A.K., Bagguley C.L.,
RA Ballabio A., Banerjee R., Barker G.E., Barlow K.F., Barrett I.P.,
RA Bates K.N., Beare D.M., Beasley H., Beasley O., Beck A., Bethel G.,
RA Blechschmidt K., Brady N., Bray-Allen S., Bridgeman A.M., Brown A.J.,
RA Brown M.J., Bonnin D., Bruford E.A., Buhay C., Burch P., Burford D.,
RA Burgess J., Burrill W., Burton J., Bye J.M., Carder C., Carrel L.,
RA Chako J., Chapman J.C., Chavez D., Chen E., Chen G., Chen Y., Chen Z.,
RA Chinault C., Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA Corby N., Connor R.E., David R., Davies J., Davis C., Davis J., Delgado O.,
RA Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S., Draper H.,
RA Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I., Eades T.,
RA Ellwood M., Emery-Cohen A., Errington H., Evans K.L., Faulkner L.,
RA Francis F., Frankland J., Fraser A.E., Galgoczy P., Gilbert J., Gill R.,
RA Gloeckner G., Gregory S.G., Gribble S., Griffiths C., Grocock R., Gu Y.,
RA Gwilliam R., Hamilton C., Hart E.A., Hawes A., Heath P.D., Heitmann K.,
RA Hennig S., Hernandez J., Hinzmann B., Ho S., Hoffs M., Howden P.J.,
RA Huckle E.J., Hume J., Hunt P.J., Hunt A.R., Isherwood J., Jacob L.,
RA Johnson D., Jones S., de Jong P.J., Joseph S.S., Keenan S., Kelly S.,
RA Kershaw J.K., Khan Z., Kioschis P., Klages S., Knights A.J., Kosiura A.,
RA Kovar-Smith C., Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L.,
RA Liu W., Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T., Milne S.,
RA Miner G., Mistry S.L., Morgan M., Morris S., Mueller I., Mullikin J.C.,
RA Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N., Okwuonu G., Palmer S.,
RA Pandian R., Parker D., Parrish J., Pasternak S., Patel D., Pearce A.V.,
RA Pearson D.M., Pelan S.E., Perez L., Porter K.M., Ramsey Y., Reichwald K.,
RA Rhodes S., Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T., Teague B.,
RA Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S., Tromans A.C.,
RA d'Urso M., Verduzco D., Villasana D., Waldron L., Wall M., Wang Q.,
RA Warren J., Warry G.L., Wei X., West A., Whitehead S.L., Whiteley M.N.,
RA Wilkinson J.E., Willey D.L., Williams G., Williams L., Williamson A.,
RA Williamson H., Wilming L., Woodmansey R.L., Wray P.W., Yen J., Zhang J.,
RA Zhou J., Zoghbi H., Zorilla S., Buck D., Reinhardt R., Poustka A.,
RA Rosenthal A., Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A., Nelson D.L.,
RA Weinstock G., Sulston J.E., Durbin R.M., Hubbard T., Gibbs R.A., Beck S.,
RA Rogers J., Bentley D.R.;
RT "The DNA sequence of the human X chromosome.";
RL Nature 434:325-337(2005).
RN [4]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX PubMed=15489334; DOI=10.1101/gr.2596504;
RG The MGC Project Team;
RT "The status, quality, and expansion of the NIH full-length cDNA project:
RT the Mammalian Gene Collection (MGC).";
RL Genome Res. 14:2121-2127(2004).
RN [5]
RP INVOLVEMENT IN XLID98, AND CHROMOSOMAL REARRANGEMENT.
RX PubMed=23615299; DOI=10.1093/hmg/ddt187;
RA Van Maldergem L., Hou Q., Kalscheuer V.M., Rio M., Doco-Fenzy M.,
RA Medeira A., de Brouwer A.P., Cabrol C., Haas S.A., Cacciagli P.,
RA Moutton S., Landais E., Motte J., Colleaux L., Bonnet C., Villard L.,
RA Dupont J., Man H.Y.;
RT "Loss of function of KIAA2022 causes mild to severe intellectual disability
RT with an autism spectrum disorder and impairs neurite outgrowth.";
RL Hum. Mol. Genet. 22:3306-3314(2013).
RN [6]
RP SUBCELLULAR LOCATION.
RX PubMed=24071057; DOI=10.1016/j.neuint.2013.09.011;
RA Magome T., Hattori T., Taniguchi M., Ishikawa T., Miyata S., Yamada K.,
RA Takamura H., Matsuzaki S., Ito A., Tohyama M., Katayama T.;
RT "XLMR protein related to neurite extension (Xpn/KIAA2022) regulates cell-
RT cell and cell-matrix adhesion and migration.";
RL Neurochem. Int. 63:561-569(2013).
RN [7]
RP INVOLVEMENT IN XLID98.
RX PubMed=26576034; DOI=10.1002/ajmg.a.37479;
RA Farach L.S., Northrup H.;
RT "KIAA2022 nonsense mutation in a symptomatic female.";
RL Am. J. Med. Genet. A 170:703-706(2016).
RN [8]
RP VARIANTS XLID98 322-ARG--ILE-1516 DEL AND 705-GLN--ILE-1516 DEL.
RX PubMed=25900396; DOI=10.1002/ajmg.a.37002;
RA Kuroda Y., Ohashi I., Naruto T., Ida K., Enomoto Y., Saito T., Nagai J.,
RA Wada T., Kurosawa K.;
RT "Delineation of the KIAA2022 mutation phenotype: two patients with X-linked
RT intellectual disability and distinctive features.";
RL Am. J. Med. Genet. A 167:1349-1353(2015).
RN [9]
RP VARIANTS XLID98 146-CYS--ILE-1516 DEL; 218-ARG--ILE-1516 DEL;
RP 318-GLN--ILE-1516 DEL; 322-ARG--ILE-1516 DEL; 481-ARG--ILE-1516 DEL AND
RP 628-ARG--ILE-1516 DEL.
RX PubMed=27358180; DOI=10.1136/jmedgenet-2016-103909;
RG EuroEPINOMICS-RES MAE working group;
RA de Lange I.M., Helbig K.L., Weckhuysen S., Moeller R.S., Velinov M.,
RA Dolzhanskaya N., Marsh E., Helbig I., Devinsky O., Tang S., Mefford H.C.,
RA Myers C.T., van Paesschen W., Striano P., van Gassen K., van Kempen M.,
RA de Kovel C.G., Piard J., Minassian B.A., Nezarati M.M., Pessoa A.,
RA Jacquette A., Maher B., Balestrini S., Sisodiya S., Warde M.T.,
RA De St Martin A., Chelly J., van 't Slot R., Van Maldergem L.,
RA Brilstra E.H., Koeleman B.P.;
RT "De novo mutations of KIAA2022 in females cause intellectual disability and
RT intractable epilepsy.";
RL J. Med. Genet. 53:850-858(2016).
RN [10]
RP VARIANTS XLID98 146-CYS--ILE-1516 DEL; 318-GLN--ILE-1516 DEL;
RP 322-ARG--ILE-1516 DEL; 481-ARG--ILE-1516 DEL AND 628-ARG--ILE-1516 DEL.
RX PubMed=27568816; DOI=10.1111/cge.12854;
RA Webster R., Cho M.T., Retterer K., Millan F., Nowak C., Douglas J.,
RA Ahmad A., Raymond G.V., Johnson M.R., Pujol A., Begtrup A., McKnight D.,
RA Devinsky O., Chung W.K.;
RT "De novo loss of function mutations in KIAA2022 are associated with
RT epilepsy and neurodevelopmental delay in females.";
RL Clin. Genet. 91:756-763(2017).
CC -!- FUNCTION: Involved in neurite outgrowth by regulating cell-cell
CC adhesion via the N-cadherin signaling pathway. May act by regulating
CC expression of protein-coding genes, such as N-cadherins and integrin
CC beta-1 (ITGB1). {ECO:0000250|UniProtKB:D3ZGX1}.
CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:24071057}. Cytoplasm
CC {ECO:0000250|UniProtKB:Q5DTT1}.
CC -!- TISSUE SPECIFICITY: Highly expressed in fetal and adult brain,
CC predominantly in the cerebral cortex and the cerebellum. Also expressed
CC in other tissues but to a lesser extent. {ECO:0000269|PubMed:15466006}.
CC -!- DISEASE: Intellectual developmental disorder, X-linked 98 (XLID98)
CC [MIM:300912]: A disorder characterized by significantly below average
CC general intellectual functioning associated with impairments in
CC adaptive behavior and manifested during the developmental period.
CC XLID98 patients show delayed psychomotor development, absent or poor
CC speech development, and postnatal growth retardation, often with
CC microcephaly. Some patients show autistic behavioral features, such as
CC stereotypic hand movements and repetitive behaviors. Additional, more
CC variable features include spasticity, axial hypotonia, seizures,
CC drooling, gastroesophageal reflux, and lack of sphincter control.
CC {ECO:0000269|PubMed:15466006, ECO:0000269|PubMed:23615299,
CC ECO:0000269|PubMed:25900396, ECO:0000269|PubMed:26576034,
CC ECO:0000269|PubMed:27358180, ECO:0000269|PubMed:27568816}. Note=The
CC disease is caused by variants affecting the gene represented in this
CC entry. A chromosomal aberration involving NEXMIF is found in patients
CC with severe intellectual disability. Pericentric inversion
CC inv(X)(p22.3;q13.2) with P2RY8 leading to inactivation of NEXMIF
CC (PubMed:15466006). XLID98 transmission pattern is consistent with X-
CC linked recessive inheritance (PubMed:23615299). In some cases, de novo
CC heterozygous loss-of-function mutations have been found in affected
CC females, while some female carriers are asymptomatic (PubMed:26576034,
CC PubMed:27358180, PubMed:27568816). The female phenotype partially
CC overlaps with the reported male phenotype but includes epilepsy as a
CC relevant feature. The variability of disease manifestation in female
CC carriers is probably due to skewed X inactivation with differential
CC expression in the brain (PubMed:26576034, PubMed:27358180,
CC PubMed:27568816). {ECO:0000269|PubMed:15466006,
CC ECO:0000269|PubMed:23615299, ECO:0000269|PubMed:26576034,
CC ECO:0000269|PubMed:27358180, ECO:0000269|PubMed:27568816}.
CC -!- SEQUENCE CAUTION:
CC Sequence=BAC23118.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC ---------------------------------------------------------------------------
CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC ---------------------------------------------------------------------------
DR EMBL; AY563507; AAT67985.1; -; mRNA.
DR EMBL; AB095942; BAC23118.1; ALT_INIT; mRNA.
DR EMBL; AL139395; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR EMBL; AL390035; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR EMBL; BC152557; AAI52558.1; -; mRNA.
DR CCDS; CCDS35337.1; -.
DR RefSeq; NP_001008537.1; NM_001008537.2.
DR AlphaFoldDB; Q5QGS0; -.
DR BioGRID; 131068; 3.
DR STRING; 9606.ENSP00000055682; -.
DR iPTMnet; Q5QGS0; -.
DR PhosphoSitePlus; Q5QGS0; -.
DR BioMuta; NEXMIF; -.
DR DMDM; 74743104; -.
DR PaxDb; Q5QGS0; -.
DR PeptideAtlas; Q5QGS0; -.
DR PRIDE; Q5QGS0; -.
DR ProteomicsDB; 63609; -.
DR Antibodypedia; 405; 15 antibodies from 8 providers.
DR DNASU; 340533; -.
DR Ensembl; ENST00000055682.12; ENSP00000055682.5; ENSG00000050030.16.
DR Ensembl; ENST00000616200.2; ENSP00000480284.1; ENSG00000050030.16.
DR GeneID; 340533; -.
DR KEGG; hsa:340533; -.
DR MANE-Select; ENST00000055682.12; ENSP00000055682.5; NM_001008537.3; NP_001008537.1.
DR UCSC; uc004eby.4; human.
DR CTD; 340533; -.
DR DisGeNET; 340533; -.
DR GeneCards; NEXMIF; -.
DR HGNC; HGNC:29433; NEXMIF.
DR HPA; ENSG00000050030; Tissue enhanced (brain).
DR MalaCards; NEXMIF; -.
DR MIM; 300524; gene.
DR MIM; 300912; phenotype.
DR neXtProt; NX_Q5QGS0; -.
DR OpenTargets; ENSG00000050030; -.
DR Orphanet; 1942; Myoclonic-astatic epilepsy.
DR Orphanet; 85277; X-linked intellectual disability, Cantagrel type.
DR PharmGKB; PA162393214; -.
DR VEuPathDB; HostDB:ENSG00000050030; -.
DR eggNOG; ENOG502QUMY; Eukaryota.
DR GeneTree; ENSGT00940000159746; -.
DR HOGENOM; CLU_250004_0_0_1; -.
DR InParanoid; Q5QGS0; -.
DR OMA; MMEPGTV; -.
DR OrthoDB; 59480at2759; -.
DR PhylomeDB; Q5QGS0; -.
DR TreeFam; TF332248; -.
DR PathwayCommons; Q5QGS0; -.
DR BioGRID-ORCS; 340533; 14 hits in 698 CRISPR screens.
DR ChiTaRS; KIAA2022; human.
DR GenomeRNAi; 340533; -.
DR Pharos; Q5QGS0; Tbio.
DR PRO; PR:Q5QGS0; -.
DR Proteomes; UP000005640; Chromosome X.
DR RNAct; Q5QGS0; protein.
DR Bgee; ENSG00000050030; Expressed in endothelial cell and 134 other tissues.
DR ExpressionAtlas; Q5QGS0; baseline and differential.
DR Genevisible; Q5QGS0; HS.
DR GO; GO:0005829; C:cytosol; IDA:HPA.
DR GO; GO:0030496; C:midbody; IDA:HPA.
DR GO; GO:0072686; C:mitotic spindle; IDA:HPA.
DR GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR GO; GO:0033629; P:negative regulation of cell adhesion mediated by integrin; IBA:GO_Central.
DR GO; GO:2000048; P:negative regulation of cell-cell adhesion mediated by cadherin; IBA:GO_Central.
DR GO; GO:0001953; P:negative regulation of cell-matrix adhesion; IBA:GO_Central.
DR GO; GO:2001223; P:negative regulation of neuron migration; IBA:GO_Central.
DR GO; GO:0007399; P:nervous system development; IEA:UniProtKB-KW.
DR InterPro; IPR032757; DUF4683.
DR InterPro; IPR042794; Nexmif.
DR PANTHER; PTHR46946; PTHR46946; 1.
DR Pfam; PF15735; DUF4683; 1.
PE 1: Evidence at protein level;
KW Chromosomal rearrangement; Cytoplasm; Developmental protein;
KW Disease variant; Intellectual disability; Neurogenesis; Nucleus;
KW Reference proteome; Transcription; Transcription regulation.
FT CHAIN 1..1516
FT /note="Neurite extension and migration factor"
FT /id="PRO_0000257844"
FT REGION 380..440
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT REGION 589..610
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT REGION 1158..1225
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT REGION 1373..1419
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT REGION 1437..1479
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT COMPBIAS 380..406
FT /note="Basic and acidic residues"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT COMPBIAS 416..440
FT /note="Polar residues"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT COMPBIAS 1158..1198
FT /note="Polar residues"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT COMPBIAS 1376..1401
FT /note="Polar residues"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT COMPBIAS 1453..1479
FT /note="Basic and acidic residues"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT VARIANT 146..1516
FT /note="Missing (in XLID98; de novo dominant mutation found
FT in females; disease phenotype includes epilepsy as a
FT feature)"
FT /evidence="ECO:0000269|PubMed:27358180,
FT ECO:0000269|PubMed:27568816"
FT /id="VAR_079039"
FT VARIANT 218..1516
FT /note="Missing (in XLID98; de novo dominant mutation found
FT in females; disease phenotype includes epilepsy as a
FT feature)"
FT /evidence="ECO:0000269|PubMed:27358180"
FT /id="VAR_079040"
FT VARIANT 318..1516
FT /note="Missing (in XLID98; de novo dominant mutation found
FT in females; disease phenotype includes epilepsy as a
FT feature)"
FT /evidence="ECO:0000269|PubMed:27358180,
FT ECO:0000269|PubMed:27568816"
FT /id="VAR_079041"
FT VARIANT 322..1516
FT /note="Missing (in XLID98; de novo dominant mutation found
FT in females; disease phenotype includes epilepsy as a
FT feature)"
FT /evidence="ECO:0000269|PubMed:25900396,
FT ECO:0000269|PubMed:27358180, ECO:0000269|PubMed:27568816"
FT /id="VAR_079042"
FT VARIANT 481..1516
FT /note="Missing (in XLID98; de novo dominant mutation found
FT in females; disease phenotype includes epilepsy as a
FT feature)"
FT /evidence="ECO:0000269|PubMed:27358180,
FT ECO:0000269|PubMed:27568816"
FT /id="VAR_079043"
FT VARIANT 628..1516
FT /note="Missing (in XLID98; de novo dominant mutation found
FT in females; disease phenotype includes epilepsy as a
FT feature)"
FT /evidence="ECO:0000269|PubMed:27358180,
FT ECO:0000269|PubMed:27568816"
FT /id="VAR_079044"
FT VARIANT 705..1516
FT /note="Missing (in XLID98)"
FT /evidence="ECO:0000269|PubMed:25900396"
FT /id="VAR_079045"
FT VARIANT 1112
FT /note="I -> T (in dbSNP:rs12851763)"
FT /id="VAR_049529"
SQ SEQUENCE 1516 AA; 167551 MW; 8B7F6575F283F669 CRC64;
MDNQQDKAIV ASANGENTLI NGVKENDSED QDVAMKSFAA LEAAAPIQPT PVAQKETLMY
PRGLLPLPSK KPCMQSPPSP LGLIEAPEHA ANSASVNAIS LTSGIAKGLN TWSLPNECEK
APFAIMEPAG MSALNGDCLM QPSRTCLGCF MESKDAVDPE PGISLKVGDL NRDYETCAVS
DIGIQCINAG ENMKYGEQLL SDQLLGFPLH KSRAGDRRET EKPDIDLEDP AQKSYYEALL
LDKCNTEEAL LANSNQDWGY FETFISESKI ELLDLCSKNE LSVNLFSEED VDNYMFDDDE
STLGSDVCSL KIRYESFQDN VRDKTTLLMQ EDAQFNFFPS VFTTCPKRES KSGALKQSSD
FSQFKVPDVS IIWGEEDKNL DKKKGKEEGQ EDKGVEKKDG KDNGEKPALN KPCSGTEVEQ
LKNPKQGHLA NSLETSGSFS DDSSFIEISY DAMGEIKDCS RYMARDTNSG SSSSQQNYGL
RAKRKVRYSE DYLYDVDSLE GEKVNERKEW LPVGSKEEDD DEWCPKKRRK VTRKEPPVII
KYIIINRFKG EKNMLVKLGK VDASETTVNL SENQLNKYAK LAPLKGFWQK KKKQRNTNTD
SIKTPFSQKQ SFEPGSFEVS FLPPARKRKS KLGNRHRIQR IPSIEISASS KQISLCNDQR
HASNHKEDGG LKGTLKSAPL GAPSCANGSH LNDITGPDSV KVKAQDTEFK GPERKVLNKI
KFKSEARLKS KKVKAAGQES KPIVQMSPLL ENQSSKANLK NEVIPGTSNS SRLSEFHEAK
AAKSSTFLPT TCSSEMPLSS ANVTTNIPVI PGGYLQTLLD ASDLSNNTSI SYFSHHSPEQ
NEGSLTQTEK SFVPLQPTQD CVLTSSSDSE LQQSSHNFKM ESSNYRNVWP NKATSGTQEF
MAEVSREIAP TQSSEFGASQ VVSMENNLTP TTYNPICLNS GGSNCNKVLY DSMQDTQLPS
DDSYQLCHFN NGEICFPFQQ GPVNMDDGRL FSFDSMAPLS VSSSNYCSLS LKSCEKDGDD
DITDDFLAHC SPKLVIQQSI DEIAPLKEST DLLDISNFTP DKFRHSSLSE MSPPDTPSLS
PQITRCESMK TLGTLKGFQE GVPGPLDSVE KIKWDCSTLS RQVQMEDGFT LNNHQFQFHM
FNDEDSVSLL QKNPCLSTFN DPSGQISTNN KVSKSRKKSS PSKSGAMNQS SSQKNTRKKS
LKGNNKGIEK PPGKNSRQVP KSTKKGKYMA AINGEKMQIG IGRGGSQTNT ISSTGKTLAE
CIQHGGPMAS MKMPSQKGLS GDWALGKESS PGWSDMSMGT NTNSLLDDDQ REFQEPSYIL
SNIASGMADV QRFMMASIEP LWEPMEHHGD PNIFYSPESN SLKLKTLKIL AGTPQESKKK
INSGSQGATK NHRSIKGVSK SNGKTAIGDP GRANMPGYNE DSRSTFFDKK YSNMSTLGNN
GPTHKKLYRH KSSSKALRDE KCKGKHMERE QVHKDESGTA SFEKLRDSDY NLLKAETTFW
VLPVFEEETR IFQKDI
